arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

Lite Strategy, Inc.

LITS
$0.97 ▼ -0.11 (-10.41%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
73 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
9
Health
Poor
Bearish
auto_awesome

Analytical Summary

Lite Strategy, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -21.6% ↗
FCF / Share None
Trailing P/E —
Price / Book 0.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

73-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-13.02M
↓ -384.3% —
Operating Margin Operating profit as % of sales
84.7%
↑ +130.4% —
FCF / Share Free cash flow per share
$-0.04
↑ +17.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
3
Cash Quality ↓
25

Dividend History

Dividend / share · sourced from SEC filings
$1.75 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 25 years · 73 quarters